| Trial ID: | L6346 |
| Source ID: | NCT03164187
|
| Associated Drug: |
Diabeton 60 Mr
|
| Title: |
Evaluation of Type 2 Diabetes Treatment
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes
|
| Interventions: |
DRUG: Diabeton 60 MR
|
| Outcome Measures: |
Primary: Decrease in HbA1c, over 4 months|Percentage of patients achieving HbA1c level ≤ 7 %, week 16. | Secondary: number of hypoglycemia episodes, Week 0, 2, 4, 6, 8 and week 16.|Mean daily dosage of Diabeton MR, Week 2, 4, 6, 8 and 16
|
| Sponsor/Collaborators: |
Sponsor: Servier Affaires Médicales
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
105
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2016-09-01
|
| Completion Date: |
2017-06-10
|
| Results First Posted: |
|
| Last Update Posted: |
2024-07-25
|
| Locations: |
Azerbaijan Republic Ministry of Health Republic Endocrinology Center, Baku, AZ 1/122, Azerbaijan|Azer-Turk Med clinic, Baku, AZ 1025, Azerbaijan|Hospital of oil workers, polyclinics and private clinics, Baku, AZ 1025, Azerbaijan|Medical Clinic of Azerbaijan Medical University, Baku, AZ-1078, Azerbaijan
|
| URL: |
https://clinicaltrials.gov/show/NCT03164187
|
